JP7095990B2 - 線維症を治療するための組成物及び方法 - Google Patents

線維症を治療するための組成物及び方法 Download PDF

Info

Publication number
JP7095990B2
JP7095990B2 JP2017515820A JP2017515820A JP7095990B2 JP 7095990 B2 JP7095990 B2 JP 7095990B2 JP 2017515820 A JP2017515820 A JP 2017515820A JP 2017515820 A JP2017515820 A JP 2017515820A JP 7095990 B2 JP7095990 B2 JP 7095990B2
Authority
JP
Japan
Prior art keywords
cancer
fibrosis
day
pharmaceutical composition
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017515820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529364A5 (https=
JP2017529364A (ja
Inventor
ラマチャンドラン ムラリ
アイダ ハブテジオン
スティーブン ジェイ． パンドル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2017529364A publication Critical patent/JP2017529364A/ja
Publication of JP2017529364A5 publication Critical patent/JP2017529364A5/ja
Application granted granted Critical
Publication of JP7095990B2 publication Critical patent/JP7095990B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2017515820A 2014-09-18 2015-09-18 線維症を治療するための組成物及び方法 Active JP7095990B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052111P 2014-09-18 2014-09-18
US62/052,111 2014-09-18
PCT/US2015/050906 WO2016044707A1 (en) 2014-09-18 2015-09-18 Compositions and methods for treating fibrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020148662A Division JP2020203922A (ja) 2014-09-18 2020-09-04 線維症を治療するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2017529364A JP2017529364A (ja) 2017-10-05
JP2017529364A5 JP2017529364A5 (https=) 2018-10-04
JP7095990B2 true JP7095990B2 (ja) 2022-07-05

Family

ID=55533900

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017515820A Active JP7095990B2 (ja) 2014-09-18 2015-09-18 線維症を治療するための組成物及び方法
JP2020148662A Withdrawn JP2020203922A (ja) 2014-09-18 2020-09-04 線維症を治療するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020148662A Withdrawn JP2020203922A (ja) 2014-09-18 2020-09-04 線維症を治療するための組成物及び方法

Country Status (4)

Country Link
US (3) US10245298B2 (https=)
EP (1) EP3194446B1 (https=)
JP (2) JP7095990B2 (https=)
WO (1) WO2016044707A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3194446B1 (en) 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA163200A (en) 1915-02-20 1915-06-15 William James Davidson Ash sifting shovel
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US4747825A (en) 1984-06-29 1988-05-31 Ferring Laboratories, Inc. Apparatus and methodology for pulsed administration of growth promoting agents
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
US4723958A (en) 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4965251A (en) 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
DE10399032I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
JP4236698B2 (ja) 1990-11-26 2009-03-11 ジェネティックス インスティチュート，リミテッド ライアビリティ カンパニー 宿主細胞でのｐａｃｅの発現およびその使用法
US5270181A (en) 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
CN1091138A (zh) 1992-08-27 1994-08-24 迪金研究有限公司 疫苗
US5403590A (en) 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
US5622856A (en) 1995-08-03 1997-04-22 Avigen High efficiency helper system for AAV vector production
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6004797A (en) 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US6048551A (en) 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
AU5756100A (en) * 1999-06-21 2001-01-09 Genetics Institute Inc. Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
CA2404763A1 (en) * 1999-11-11 2001-05-17 Raj K. Puri Mutated il-13 molecules and their uses
EP2990420B1 (en) * 2000-05-26 2016-12-21 Immunex Corporation Use of interleukin-4 receptor antibodies and compositions thereof
US7785580B2 (en) * 2003-08-29 2010-08-31 Aerovance, Inc. Modified IL-4 mutein receptor antagonists
AU2005219837A1 (en) * 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 sepecific polypetides and therapeutic uses thereof
US20050287066A1 (en) 2004-06-28 2005-12-29 Monoace, Inc. Anti-rat angiotensin I-converting enzyme (ACE, CD143) monoclonal antibodies and uses thereof
US20110268749A1 (en) 2007-07-31 2011-11-03 The Government of the US as Represented by the Secretary Department of Health and Human Services Treatment of cancer via targeting of il-13 receptor-alpha2
CA2698666A1 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US20110256130A1 (en) * 2008-12-01 2011-10-20 Joshua Robert Schultz Methods of treating inflammatory disorders
US9296785B2 (en) 2009-04-17 2016-03-29 Wake Forest University Health Sciences IL-13 receptor binding peptides
TWI732259B (zh) * 2010-12-16 2021-07-01 美商建南德克公司 關於th2抑制作用之診斷及治療
HK1197159A1 (en) * 2011-05-25 2015-01-09 Intermune, Inc. Pirfenidone and anti-fibrotic therapy in selected patients
EP3194446B1 (en) 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Ａｒｔｈｒｉｔｉｓ ＆ Ｒｈｅｕｍａｔｉｓｍ，２００３年，Ｖｏｌ．４８，Ｎｏ．８，ｐ２２７５－２２８４
Ｅｕｒｏｐｅａｎ Ｊｏｕｒｎａｌ ｏｆ Ｉｍｍｕｎｏｌｏｇｙ，１９９８年，Ｖｏｌ．２８，Ｎｏ．９，ｐ２６１９－２６２９
Ｌｉｖｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ，２００５年，Ｖｏｌ．２５、Ｎｏ．２，ｐ４２０－４２８
ＰＬｏＳ Ｏｎｅ，２０１３年，Ｖｏｌ．８，Ｎｏ．１２，ｅ８１８９１，ｐ１－１２，ｄｏｉ：１０．１３７１／ｊｏｕｒｎａｌ．ｐｏｎｅ．００８１８９１
アレルギー，２００５年，Ｖｏｌ．５４，Ｎｏ．１，ｐ７－１１

Also Published As

Publication number Publication date
US20190183967A1 (en) 2019-06-20
US20250121026A1 (en) 2025-04-17
EP3194446A4 (en) 2018-03-14
JP2020203922A (ja) 2020-12-24
US10245298B2 (en) 2019-04-02
EP3194446B1 (en) 2022-10-26
EP3194446A1 (en) 2017-07-26
US11547738B2 (en) 2023-01-10
JP2017529364A (ja) 2017-10-05
WO2016044707A1 (en) 2016-03-24
US20170189471A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
ES2739129T3 (es) IL-22 para uso en el tratamiento de la enfermedad gastrointestinal del injerto contra el huesped
US20250121026A1 (en) Compositions and methods for treating fibrosis
EP4194001B1 (en) Enterically delivered bitter oligopeptides for the treatment of type 2 diabetes and obesity
JP6921755B2 (ja) 脳腫瘍幹細胞の成長、遊走および浸潤性を低下させ脳腫瘍患者の生存率を改善する方法および組成物
JP2007020586A5 (https=)
CN101370509A (zh) 化合物连同γ辐射在用于治疗癌症中的应用
Tan et al. Combination of low‐dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities
ES2928879T3 (es) Linfocitos citolíticos naturales
KR20160061423A (ko) 감염성 질환 및 소화관 염증에 대한 약물 표적으로서 퍼포린-2 활성화제 및 억제제
TWI238191B (en) IL-17 like molecules and uses thereof
JP5049011B2 (ja) 変異体ｌｉｇｈｔによるｔ細胞腫瘍浸潤の増大
KR102753455B1 (ko) 암 및 자가면역 질환을 치료하기 위한 조성물 및 방법
US9581598B2 (en) Diagnosis and treatment of brain tumor
Emancipator Prospects and perspectives on IgA nephropathy from animal models.
ES2363972T3 (es) Vectores de adn.
WO2017019982A1 (en) Compositions and methods for treating acne
JP7374502B2 (ja) Ｏｃａ－ｂペプチドコンジュゲート及び処置方法
AU2024246543A1 (en) Methods for enhancing the immunogenicity of cellular vaccines
Bettenworth et al. S1642 New Tools for In Vivo Imaging of Murine DSS-Colitis-Mrp14-Directed Fluorescence-Mediated Molecular Tomography (FMT) and High-Resolution Ultrasound Imaging
WO2025101551A1 (en) Prostate-specific membrane antigen (psma)-binding peptides and method of use
WO2024102387A2 (en) Fusion polypeptides and formulations thereof
US20190282616A1 (en) Macrophages redirect phagocytosis by non-professional phagocytes and influence inflammation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200904

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200904

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20201002

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20201005

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20201127

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20201202

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210302

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210714

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20211018

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220114

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220415

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220516

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220608

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220608

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220623

R150 Certificate of patent or registration of utility model

Ref document number: 7095990

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250